Peringatan Keamanan

Osteoporosis with increasing duration of use, bleeding, alopecia, heparin induced thrombocytopenia (HIT). All of these adverse drug reactions occur less with LMWH compared to unfractionated heparin. Tinzaparin showed no toxic effects at doses up to 5 mg/kg in mice, rats, or dogs in standard acute, subacute, and chronic toxicity studies.

Tinzaparin

DB06822

small molecule approved

Deskripsi

Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III (ATIII). This complex greatly accelerates the inhibition of factor Xa. It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally. LMWHs are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Anti-Xa activity is 82 minutes. Anti-IIa activity is 71 minutes.
Volume Distribusi Anti-Xa activity is 4 L. Anti-IIa activity is 10.9 L
Klirens (Clearance) Clearance is dose-dependant. The clearance of tinzaparin based on anti-Xa activity ranged from 1.14 to 2.04 L/hr

Absorpsi

Subcutaneous injection - about 90% when measured as anti-Xa activity versus 67% for anti-IIa activity.

Metabolisme

Sulfation and polymerization occurs in the liver.

Rute Eliminasi

Linear elimination through kidneys

Interaksi Makanan

1 Data
  • 1. Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Interaksi Obat

860 Data
Apixaban Apixaban may increase the anticoagulant activities of Tinzaparin.
Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Tinzaparin.
Dasatinib The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Tinzaparin.
Deferasirox The risk or severity of gastrointestinal bleeding can be increased when Tinzaparin is combined with Deferasirox.
Ursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Tinzaparin is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Tinzaparin is combined with Glycochenodeoxycholic Acid.
Cholic Acid The risk or severity of bleeding and bruising can be increased when Tinzaparin is combined with Cholic Acid.
Glycocholic acid The risk or severity of bleeding and bruising can be increased when Tinzaparin is combined with Glycocholic acid.
Deoxycholic acid The risk or severity of bleeding and bruising can be increased when Tinzaparin is combined with Deoxycholic acid.
Taurocholic acid The risk or severity of bleeding and bruising can be increased when Tinzaparin is combined with Taurocholic acid.
Obeticholic acid The risk or severity of bleeding and bruising can be increased when Tinzaparin is combined with Obeticholic acid.
Chenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Tinzaparin is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Tinzaparin is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Tinzaparin is combined with Tauroursodeoxycholic acid.
Bamet-UD2 The risk or severity of bleeding and bruising can be increased when Tinzaparin is combined with Bamet-UD2.
Dehydrocholic acid The risk or severity of bleeding and bruising can be increased when Tinzaparin is combined with Dehydrocholic acid.
Hyodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Tinzaparin is combined with Hyodeoxycholic Acid.
Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Tinzaparin.
Ibrutinib The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Tinzaparin.
Obinutuzumab The risk or severity of bleeding and hemorrhage can be increased when Tinzaparin is combined with Obinutuzumab.
Rivaroxaban Tinzaparin may increase the anticoagulant activities of Rivaroxaban.
Sugammadex The risk or severity of bleeding and hemorrhage can be increased when Tinzaparin is combined with Sugammadex.
Tibolone Tibolone may increase the anticoagulant activities of Tinzaparin.
Tipranavir The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Tinzaparin.
Urokinase Urokinase may increase the anticoagulant activities of Tinzaparin.
Vitamin E Vitamin E may increase the anticoagulant activities of Tinzaparin.
Vorapaxar The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Tinzaparin.
Trandolaprilat The risk or severity of hyperkalemia can be increased when Trandolaprilat is combined with Tinzaparin.
Moexiprilat The risk or severity of hyperkalemia can be increased when Moexiprilat is combined with Tinzaparin.
Cilazaprilat The risk or severity of hyperkalemia can be increased when Cilazaprilat is combined with Tinzaparin.
Ginkgo biloba Ginkgo biloba may increase the anticoagulant activities of Tinzaparin.
Ifosfamide The risk or severity of bleeding can be increased when Ifosfamide is combined with Tinzaparin.
Quinine The therapeutic efficacy of Tinzaparin can be increased when used in combination with Quinine.
Quinidine The therapeutic efficacy of Tinzaparin can be increased when used in combination with Quinidine.
Tamoxifen The risk or severity of bleeding can be increased when Tamoxifen is combined with Tinzaparin.
Toremifene The risk or severity of bleeding can be increased when Toremifene is combined with Tinzaparin.
Corticorelin ovine triflutate The risk or severity of hypotension and sinus node depression can be increased when Tinzaparin is combined with Corticorelin ovine triflutate.
Oritavancin The therapeutic efficacy of Tinzaparin can be decreased when used in combination with Oritavancin.
Streptokinase Streptokinase may increase the anticoagulant activities of Tinzaparin.
Telavancin The therapeutic efficacy of Tinzaparin can be decreased when used in combination with Telavancin.
Palifermin The serum concentration of Palifermin can be increased when it is combined with Tinzaparin.
Pentoxifylline The therapeutic efficacy of Tinzaparin can be increased when used in combination with Pentoxifylline.
Pentosan polysulfate Pentosan polysulfate may increase the anticoagulant activities of Tinzaparin.
Levocarnitine The therapeutic efficacy of Tinzaparin can be increased when used in combination with Levocarnitine.
Diethylstilbestrol Diethylstilbestrol may decrease the anticoagulant activities of Tinzaparin.
Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Tinzaparin.
Conjugated estrogens Conjugated estrogens may decrease the anticoagulant activities of Tinzaparin.
Mestranol The risk or severity of adverse effects can be increased when Mestranol is combined with Tinzaparin.
Estrone sulfate Estrone sulfate may decrease the anticoagulant activities of Tinzaparin.
Quinestrol Quinestrol may decrease the anticoagulant activities of Tinzaparin.
Hexestrol Hexestrol may decrease the anticoagulant activities of Tinzaparin.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Tinzaparin.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Tinzaparin.
Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Tinzaparin.
Esterified estrogens Esterified estrogens may decrease the anticoagulant activities of Tinzaparin.
Zeranol Zeranol may decrease the anticoagulant activities of Tinzaparin.
Equol Equol may decrease the anticoagulant activities of Tinzaparin.
Methallenestril Methallenestril may decrease the anticoagulant activities of Tinzaparin.
Epimestrol Epimestrol may decrease the anticoagulant activities of Tinzaparin.
Moxestrol Moxestrol may decrease the anticoagulant activities of Tinzaparin.
Estradiol acetate Estradiol acetate may decrease the anticoagulant activities of Tinzaparin.
Estradiol benzoate Estradiol benzoate may decrease the anticoagulant activities of Tinzaparin.
Estradiol cypionate Estradiol cypionate may decrease the anticoagulant activities of Tinzaparin.
Estradiol valerate Estradiol valerate may decrease the anticoagulant activities of Tinzaparin.
Biochanin A Biochanin A may decrease the anticoagulant activities of Tinzaparin.
Formononetin Formononetin may decrease the anticoagulant activities of Tinzaparin.
Estriol Estriol may decrease the anticoagulant activities of Tinzaparin.
Limaprost The risk or severity of adverse effects can be increased when Limaprost is combined with Tinzaparin.
Icosapent The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Tinzaparin.
Mesalazine The risk or severity of bleeding can be increased when Mesalazine is combined with Tinzaparin.
Indomethacin The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Tinzaparin.
Nabumetone The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Tinzaparin.
Ketorolac The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Tinzaparin.
Tenoxicam The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Tinzaparin.
Celecoxib The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Tinzaparin.
Tolmetin The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Tinzaparin.
Rofecoxib The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Tinzaparin.
Piroxicam The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Tinzaparin.
Fenoprofen The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Tinzaparin.
Valdecoxib The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Tinzaparin.
Diclofenac The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Tinzaparin.
Sulindac The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Tinzaparin.
Flurbiprofen The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Tinzaparin.
Etodolac The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Tinzaparin.
Mefenamic acid The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Tinzaparin.
Naproxen The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Tinzaparin.
Sulfasalazine The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Tinzaparin.
Phenylbutazone The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Tinzaparin.
Meloxicam The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Tinzaparin.
Carprofen The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Tinzaparin.
Diflunisal The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Tinzaparin.
Salicylic acid The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Tinzaparin.
Meclofenamic acid The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Tinzaparin.
Oxaprozin The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Tinzaparin.
Ketoprofen The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Tinzaparin.
Balsalazide The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Tinzaparin.
Olsalazine The risk or severity of bleeding can be increased when Tinzaparin is combined with Olsalazine.
Lumiracoxib The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Tinzaparin.
Magnesium salicylate The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Tinzaparin.
Salsalate The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Tinzaparin.

Target Protein

Antithrombin-III SERPINC1
Integrin alpha-4 ITGA4
Stromal cell-derived factor 1 CXCL12

Referensi & Sumber

Artikel (PubMed)
  • PMID: 7528134
    Friedel HA, Balfour JA: Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders. Drugs. 1994 Oct;48(4):638-60.
  • PMID: 9278462
    Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, Laurent M, Hirsch JL, Ferrari E, Bosson JL, Mottier D, Beau B: A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med. 1997 Sep 4;337(10):663-9.
  • PMID: 10348714
    Planes A, Samama MM, Lensing AW, Buller HR, Barre J, Vochelle N, Beau B: Prevention of deep vein thrombosis after hip replacement--comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost. 1999 Jan;81(1):22-5.
  • PMID: 15212562
    Cheer SM, Dunn CJ, Foster R: Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease. Drugs. 2004;64(13):1479-502.
  • PMID: 20568836
    Hoy SM, Scott LJ, Plosker GL: Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis. Drugs. 2010 Jul 9;70(10):1319-47. doi: 10.2165/11203710-000000000-00000.
  • PMID: 11011803
    Hedner U: Development of tinzaparin: a heparinase-digested low-molecular-weight heparin. Semin Thromb Hemost. 2000;26 Suppl 1:23-9.
  • PMID: 11234669
    Pautas E, Siguret V, d'Urso M, Laurent M, Gaussem P, Fevrier M, Durand-Gasselin B: Monitoring of tinzaparin in a ten day treatment dose in elderly patients. Rev Med Interne. 2001 Feb;22(2):120-6.
  • PMID: 14640933
    Pineo GF, Hull RD: Tinzaparin in the treatment of venous thromboembolism. Expert Opin Pharmacother. 2003 Dec;4(12):2355-62.
Menampilkan 8 dari 10 artikel.

Contoh Produk & Brand

Produk: 15 • International brands: 0
Produk
  • Innohep
    Injection • 20000 [iU]/1mL • Subcutaneous • US • Approved
  • Innohep
    Injection, solution • 20000 [iU]/1mL • Subcutaneous • US • Approved
  • Innohep
    Solution • 10000 unit / mL • Subcutaneous • Canada • Approved
  • Innohep
    Solution • 20000 unit / mL • Subcutaneous • Canada • Approved
  • Innohep
    Solution • 10000 unit / mL • Subcutaneous • Canada • Approved
  • Innohep
    Solution • 20000 unit / mL • Subcutaneous • Canada • Approved
  • Innohep
    Solution • 10000 unit / mL • Subcutaneous • Canada • Approved
  • Innohep
    Solution • 10000 unit / mL • Subcutaneous • Canada • Approved
Menampilkan 8 dari 15 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul